It binds specifically to B-tubulin subunit of microtubule and appears to antagonise the disassembly of this cyto-skeletal protein. Arrest in mitosis follows. The cell killing is dependent on both drug concentration and duration of cell exposure.
Metastatic ovarian and breast cancer.
It is administered as influsion. After infusion it undergoes intensive P450-mediated hepatic metabolism. The clearance of Paclitaxel is saturable and decreases with increasing dose of dose rate.
Hypersensitivity to Paclitaxel.
Bone marrow depression, hypersensitivity reactions, myalgia, chest pain, bradycardia, a stocking-glove sensory neuropathy, mucositis, nausea, vomiting, diarrhoea, alopecia. Altered liver function tests.
Safety and efficacy in children has not been established. Monitor haematological functions. The drug should be administered under supervision of a physician experienced in use of cancer chemotherapy.
Following 1, 3, 6 & 24 hours infusion at dosing levels of 15 - 275mg / m2, mean terminal half-life ranges from 51.1 - 52.7 hours.
30mg / 5ml Injection,
Shree Ganesh
Pharmaceuticals
|
|||||||||||||||||||||
|
Disclaimer
:
This guide is provided for information purposes only, and for use
of a registered medical practitioner or a hospital or a laboratory only.
The authors, webmaster, or respective references / links are no way
responsible for the content of the information. Although a concerted
effort has been made to ensure the validity of the information contained
in this document, we give no
assurance for the accuracy of the information in this documents. |